Professor of Clinical Neurology and Psychiatry
Director, Division of Cognitive Neurology
Center for Cognitive and Memory Disorders
395 W. 12th Ave.
614-293-4969
Research Interests:
- Cognitive assessment
- Dementia
- Alzheimer’s disease
- Mild cognitive impairment
- Dementia with Lewy bodies
- Frontotemporal dementia
- Behavioral disturbances in dementia
Research Lab Goals: Dr. Scharre conducts clinical research in dementia and mild cognitive impairment that has been funded by NIH, foundations and industry. He has many active grants including clinical drug trials using cognitive enhancers and behavioral therapies; functional neuroimaging studies using PET, SPECT and MRI; and screening for mild cognitive impairment and early dementia diagnosis.
Current Research:
-
Roche, Scharre (Site PI), 05/01/2017 - 08/30/2021
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) (CREAD 2).
The major goal of this study is to measure the efficacy and safety of BN29553 in patients with prodromal to mild Alzheimer’s disease.
Role: Site PI
Neurim, Scharre (Site PI), 05/01/2017 - 09/30/2020
Randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study of piromelatine in patients with mild dementia due to Alzheimer's disease (NeuP11-AD2).
The major goal of this study is to measure the efficacy and safety of NeuP11-AD2 in patients with mild Alzheimer’s disease.
Role: Site PI
NIA / pharmaceutical corporations, Scharre (Site PI), 09/15/2016 - 07/31/2020
Alzheimer’s disease Neuroimaging Initiative 3 (ADNI3).
The major goal of this project is to identify serial biomarker and neuroimaging techniques that are sensitive and change quickly as a subject goes from normal to mild cognitive impairment to dementia.
Role: Site PI
AstraZeneca and Eli Lilly, Scharre (Site PI), 05/01/2017 - 09/30/2020
A randomized, double-blind, placebo-controlled and delayed-start study of LY3314814 in mild Alzheimer's disease dementia (the Daybreak study).
The major goal of this study is to measure the efficacy and safety of LY3314814 in patients with mild Alzheimer’s disease.
Role: Site PI
Avanir Pharmaceuticals, Scharre (Site PI), 08/31/2015 - 08/30/2018
A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of AVP-786 (deuerated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of Alzheimer’s disease.
The major goal of this study is to measure the efficacy and safety of AVP-786 in patients with behaviors and Alzheimer’s disease.
Role: Site PI
Biogen, Scharre (Site PI), 09/10/2015 - 09/10/2020
A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer's disease.
The major goal of this study is to measure the efficacy and safety of BIIB037 in patients with Alzheimer’s disease.
Role: Site PI
Merck, Scharre (Site PI), 03/01/2014 – 12/30/2017
A phase III, randomized, placebo-controlled, parallel-group, double-blind clinical trial to study the efficacy and safety of MK-8931 (SCH 900931) in subjects with amnestic mild cognitive impairment due to Alzheimer's Disease (prodromal AD)
The major goal of this study is to measure the efficacy and safety of MK-8931 in patients with prodromal Alzheimer’s disease.
Role: Site PI
Brain Test, Inc., Scharre (PI), 07/01/2014 - 07/01/2017
Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE)
The major goal of this study is evaluate the validity of the digital SAGE cognitive assessment tool.
Role: PI
Ali Rezai, MD, Scharre (Co-PI), 06/29/2011 – 7/31/2017
Deep brain stimulation (DBS) for treatment of the cognitive, behavioral, and functional disability of Alzheimer’s disease.
The major goal of this study is to measure the efficacy and safety of deep brain stimulation in patients with Alzheimer’s disease and providing information for planning subsequent clinical trials.
Role: Leading the neurology team, determining site and type of stimulation, longitudinal evaluation of subjects
Phylogeny, Inc., Scharre (PI), 01/01/2012 - 01/01/2018
Cerebral fluid (CSF) and blood repository (Buckeye Biospecimen Repository): evaluating biomarkers for degenerative brain conditions
The major goal of this study is to collect and measure blood and CSF for biomarkers of degenerative disease.
Role: PI
Mangurian Foundation, Scharre (PI), 01/14/2011 – 12/31/2020
Diagnosing dementia with Lewy bodies and Parkinson’s disease dementia
The major goal of this project is to identify serial biomarker and neuroimaging techniques that are sensitive and change quickly as a subject goes from normal to mild cognitive impairment to dementia.
Research Techniques: Neuroimaging, PET, MRI, lumbar puncture with cerebrospinal analysis, cognitive assessments
Background: He has published journal papers, book chapters and abstracts in the area of cognitive neurology including dementia, Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, chorea-acanthocytosis, frontal lobe disorders, inherited neurologic disorders, visual agnosia and optic aphasia. He has published on the neuropsychiatric aspects of neoplastic, demyelinating, infectious and inflammatory diseases of the brain; on biomarkers in Alzheimer's disease including beta-amyloid protein and tau protein; on functional neuroimaging with SPECT scanning; and on treatment of behavioral disturbances in dementia. He lectures frequently on topics of dementia, Alzheimer's disease, behavioral management of dementia and other aspects of cognitive neurology.
Dr. Scharre joined The Ohio State University Wexner Medical Center faculty in the Department of Neurology in 1993. Dr. Scharre is board certified in neurology and in behavioral neurology and neuropsychiatry with special interests in cognitive assessment, degenerative dementias and dementia-related behaviors.
Education:
MS: Physiology & Biophysics, Georgetown University
MD: Medicine, Georgetown University
Postgraduate:
Internship: Internal Medicine, Wm Beaumont Army Medical Center
Residency: Neurology, Letterman Army Medical Center
Fellowship: Neurobehavior, University of California, Los Angeles